Search

Background: Bladder extrophy is a rare congenital anomaly, it is now well reconized that an exstrophy of the bladder is associated with an increased risk of bladder cancer. Case presentation: We report the case of 34-year-old male with squamous cell carcinoma of an unreconstructed exstrophic bladder. Because of the locally advanced disease, he received neoadjuvant chemotherapy with favorable response. Then, he underwent a total cystectomy with uretero-intestinal anastamosis. Results: The patient progressed three months after the surgery. Chemotherapy was established and he received 2 cycles, however, he died 2 months later. Conclusion: Squamous cell carcinoma associated with bladder extrophy remains relatively high. These tumors tend to be aggressive, follow-up is mandatory in these cases.

Introduction: In Morocco, cervical cancer is the second most common cancer,and the third cause of death. Our department recruits more than 500 patients each year and proximally half of the cases are diagnosed at an advanced stage. Patients and methods: Between January 2011 and December 2011, all patients diagnosed with cervical cancer and treated with concurrent chemoradiotherapy were retrieved. We analyzed overall survival, local control, and defined prognostic factors influencing outcomes in this population. Results: At 3 years the overall survival rate for the cohort was 89.8% and the overall LC rate was 80.8%. The most important prognostic factors for OS and LC were the pretreatment hemoglobin, total duration of treatment, and the use of brachyteherapy. Of the included patients, 20% experienced late Grade 3 or 4 toxicity. Conclusion: The results of our study have shown that besides tumor stage, the use of brachytherapy, and lymphnode status, other factors such as pretreatment hemoglobin and treatment duration should be analyzed carefully and should be considered taking into consideration influence of all of the aforementioned factors.

Introduction: In Morocco, cervical cancer is the second most common cancer, and proximally half of the cases are diagnosed at an advanced stage. The standard treatment approach is concurrent chemoradiation followed by intracavitary brachytherapy (BT) boost to the cervix. Patients and methods: 293 patients diagnosed with cervical cancer and treated with concurrent chemoradiotherapy between January 2011 and December 2011 at our department was retrieved. We analyzed defined prognostic factors influencing outcomes. The aim of our study is to analyze the effect of the use of brachytherapy on treatment outcomes (overall survival and local control) and to report the toxicities for each treatment approach. Results: At 3 years, the use of brachytherapy as boost was found to be a significant factor impacting both OS (P=0.0001)), and LC (P=0.001). Also in the multivariate analysis, brachytherapy was an independent prognosis factor affecting both OS (hazard ratio [HR], 3.29; 95% CI, 1.50-7.21, P=0.03) and LC (hazard ratio [HR], 2.33; 95% CI, 1.30-7.21, P=0.005). Conclusion: At present, brachytherapy is still the standard approach to boost the cervix in patients with locally advanced cervical cancer.

Introduction: Treatment duration has always been related to treatment outcomes in cervical cancer. Our study is aiming to evaluate this parameter and its effect on treatments’ results in patients with locally advanced cervical cancer treated with concurrent chemo radiation. Patients and methods: Between January 2011 and December 2011, all patients diagnosed with cervical cancer and treated with concurrent chemo radiotherapy were retrieved. Treatment duration was calculated from the first day of EBRT to the last day of brachytherapy or EBRT, whichever was last to complete, Fifty-six days (8 weeks) was used as a limit, we analyzed the impact of treatment duration on the overall survival and local control. Results: The median time to complete pelvis RT was 37 days (34-42 days). A median of 15 days (13-26 days) between the last day of Pelvic RT and the start of the first Brachytherapy fraction (Pelvis RT-BT interval) was noted. The median time to complete EBRT in association with BT was55 days (50-69 days) while the median total treatment duration was 61 days (53-71 days). At 3 years the overall survival (OS) rate of the studied cohort was 89.8% and local control (LC) rate was 80.8%. In the univariate analysis, total treatment duration (>56 days) was found to be a significant factor impacting both OS (P=0.014)), and LC (P=0.014). Also in the multivariate analysis, total treatment duration was associated independently with prognosis, and affected both OS (hazard ratio [HR], 2.8; 95% CI, 1.07-7.54, P=0.035) and LC (hazard ratio [HR] 3.2; 95% CI, 1.57-6.64, P=0.001). Conclusion: Extended treatment duration significantly affects treatment outcomes in cervical cancer, efforts should be made to shorten it in a way to improve cancer prognosis.